Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study is to investigate which changes in immunological biomarkers under
 treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be
 detected.
Inclusion Criteria:

 -  Subjects with relapsing forms of MS defined by 2005 revised McDonald criteria

 -  Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5

 Exclusion Criteria:

 -  Patients with a manifestation of MS other than relapsing remitting MS

 -  Patients with a history of chronic disease of the immune system other than MS such as
 known immunodeficiency syndrome

 -  History or presence of malignancy in the last 5 years

 -  Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or
 proliferative diabetic retinopathy and uncontrolled diabetic patients

 -  Diagnosis of macular edema during Screening Phase

 -  Patients with active systemic bacterial, viral or fungal infections

 -  Negative for varicella-zoster virus IgG antibodies at Screening

 -  Patients who have been treated with cladribine, cyclophosphamide or mitoxantrone at
 any time

 -  History of cardiovascular disorder

 -  Women of child-baring potential and inadequate contraception

 Other protocol-defined inclusion/exclusion criteria may apply